- Update on immune checkpoint inhibitors in gynecological cancers
-
Heong V, Ngoi N, Tan DS
- KMID: 2413459
- J Gynecol Oncol.
- 2017 Mar;28(2):e20.
- doi: 10.3802/jgo.2017.28.e20
In recent years, progress in our understanding of immune-modulatory signaling pathways in immune cells and the tumor microenvironment (TME) has led to rejuvenated interest in cancer immunotherapy. In particular, immunotherapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know
-
Braschi-Amirfarzan M, Tirumani S, Hodi FS, Nishino M
- KMID: 2468121
- Korean J Radiol.
- 2017 Feb;18(1):42-53.
- doi: 10.3348/kjr.2017.18.1.42
Over the past five years immune-checkpoint inhibitors have dramatically changed the therapeutic landscape of advanced solid and hematologic malignancies. The currently approved immune-checkpoint inhibitors include antibodies to cytotoxic T-lymphocyte antigen-4,... -
- CITED
-
- Close
- SHARE
-
- Close
- Immune checkpoint blockade therapy for bladder cancer treatment
-
Kim J
- KMID: 2426521
- Investig Clin Urol.
- 2016 Jun;57(Suppl 1):S98-S105.
- doi: 10.4111/icu.2016.57.S1.S98
Bladder cancer remains the most immunogenic and expensive malignant tumor in the United States today. As the 4th leading cause of death from cancer in United States, Immunotherapy blocking immune... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
-
Zhu J, Wen H, Bi R, Wu Y, Wu X
- KMID: 2413203
- J Gynecol Oncol.
- 2017 Nov;28(6):e77.
- doi: 10.3802/jgo.2017.28.e77
OBJECTIVE: Programmed death-ligand 1 (PD-L1) was expressed in various tumors and antibodies targeting its receptor programmed cell death-1 (PD-1) are emerging cancer therapeutics. This study was designed to evaluate the... -
- CITED
-
- Close
- SHARE
-
- Close
